NCT02315196View on ClinicalTrials.gov

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

February 25, 2015

Primary Completion Date

February 8, 2021

Study Completion Date

July 31, 2041

Conditions
Estrogen Receptor-negative Breast CancerHER2-negative Breast CancerProgesterone Receptor-negative Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerTriple-negative Breast Cancer
Interventions
DRUG

pegylated liposomal doxorubicin hydrochloride

Given IV

DRUG

epirubicin hydrochloride

Given IV

DRUG

carboplatin

Given IV

PROCEDURE

therapeutic conventional surgery

Undergo definitive surgery

DRUG

paclitaxel

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

quality-of-life assessment

Ancillary studies

Trial Locations (1)

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Rutgers Cancer Institute of New Jersey

OTHER

lead

Rutgers, The State University of New Jersey

OTHER